Beta Bionics Q1 sales beat on PBP channel growth

Beta Bionics

21/04/2026 21:12

Overview

U.S. diabetes device maker's Q1 net sales rose 57% yr/yr, beating analyst expectations

Company raised full-year guidance for revenue and gross margin

Outlook

Beta Bionics raises 2026 revenue guidance to $131 mln-$136 mln from $130 mln-$135 mln

Company now sees 37%-39% of new patient starts reimbursed through PBP channel, up from 36%-38%

Beta Bionics lifts 2026 gross margin outlook to 57.5%-59.5% from 55.5%-57.5%

Result Drivers

PBP CHANNEL GROWTH - Net sales in the Pharmacy Benefit Plan channel rose 181% yr/yr, driving overall revenue growth

GROSS MARGIN IMPROVEMENT - Gross margin increased by 864 basis points to 59.5%

DECLINE IN NEW PATIENT STARTS - New patient starts declined by at least 10% but less than 20% sequentially versus the fourth quarter of 2025

Company press release: ID:nGNX7pjn7K

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net sales
Beat
$27.63 mln
$26.97 mln (11 Analysts)
Q1 EPS
-$0.49
Q1 Net Income
-$21.90 mln
Q1 Adjusted EBITDA
Beat
-$17.72 mln
-$19.77 mln (9 Analysts)
Q1 Income from Operations
Beat
-$24.27 mln
-$24.90 mln (11 Analysts)
Q1 Gross Profit
$16.44 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Beta Bionics Inc is $23.00, about 78.2% above its April 20 closing price of $12.91

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)